company for the Indian and global market ?
Savikalpa ' s medical products line , Shunyata , has seven SKUs at the moment . Three proprietary oral formulations , containing cannabinoids as the principal actives , along with minor concentrations of other synergistic natural compounds . We refer to these products internally as " primary formulations ", as these are the first products we have brought to market . We have three topical formulations as well , also primary products . One is a prophylactic targeting migraine , another targeting menstrual cramps , and the third targeting joint inflammation and osteoarthritis in particular .
We have recently done a limited release of our first " secondary formulation ", a polyherbal topical pain cream on which we have completed all preclinical biology investigations and which is patent pending . We are very excited about the prospects of this formulation , which we are certain will demonstrate to stakeholders what a focus on science and R & D can achieve .
Our first objective is to serve the Indian patient universe , but once we complete human clinical trials ( in the offing ), we shall take select formulations to global markets as well .
Why is the company promoting cannabinoid medicine ? How are you bridging the traditional modern approaches in the process ?
The scientific and clinical understanding of cannabinoids is still very limited . This presents an opportunity to work with these compounds -- over 160 phytocannabinoids have now been identified , but only a fraction have been characterised , and we know but a little about their role in mediating various physiological processes via the endocannabinoid system . The research universe is vast , and the therapeutic potential very high . But as mentioned earlier , the danger is that the medical potential of cannabinoids gets stymied due to unscientific approaches to promoting cannabis in pursuit of a quick buck , which can lead to push back instead of wider adoption in the medium term -- and which would be a huge disservice to millions of patients who could benefit from cannabinoid therapy , especially in a country like India .
“ Savikalpa Sciences was born out of a desire to dispel the dogma that natural product medicines are ineffective .”
BioTech
BIOVOICENEWS . COM 27